对心血管安全药理学评估的创新方法
Michael K Pugsley1, Brett R Winters1, Yevgeniya E Koshman2
1Toxicology & Safety Pharmacology, Cytokinetics, South San Francisco, CA 94080, United States of America.
这篇社论强调了安全药理学 (SP) 方法的创新,展示了用于药物安全性评估的计算建模和生物标志物开发的进展. 关键主题包括使用新型心电图参数进行心脏模型和前节律失常风险评估.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 计算生物学 计算生物学
背景情况:
- 这篇社论介绍了2023年关于安全药理学 (SP) 方法的主题问题,其中包括安全药理学学会 (SPS) 会议的内容.
- 该期刊包括138个摘要,涵盖了SP的创新,建立在2004年的传统上.
更多相关视频
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
09:17Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
Published on: August 9, 2022
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Preclinical Development: Overview
Model Approaches for Pharmacokinetic Data: Physiological Models
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
